PF-06447475 NEW
| Price | $43 | $61 | $89 |
| Package | 5mg | 10mg | 25mg |
| Supply Ability: | 10g |
| Update Time: | 2026-07-13 |
Product Details
| Product Name: PF-06447475 | CAS No.: 1527473-33-1 |
| Purity: 98.61% | Supply Ability: 10g |
| Release date: 2026/07/13 |
Product Introduction
Bioactivity
| Name | PF-06447475 |
| Description | PF-06447475 is a highly effective, specific, brain penetrant LRRK2 inhibitor with IC0 of 3/11 nM for wild type LRRK2 and G2019S LRRK2 respectively. |
| In vitro | In the macrophage cell line Raw264.7, PF-06447475 inhibits endogenous LRRK2 kinase activity with IC50 of <10 nM. [2] In astrocytes, PF-06447475 rescues LRRK2 mutation-induced defects in lysosomal morphology and function. [3] |
| In vivo | In G2019S BAC-transgenic mice, PF-06447475 (100 mg/kg, p.o.) inhibits pS935 and pS1292 phosphorylation of LRRK2 with IC50 of 103 nM and 21 nM, respectively. [1] In G2019S-LRRK2 rats, PF-06447475 (30 mg/kg, p.o.) blocks α-synuclein-induced dopaminergic neurodegeneration and attenuates neuroinflammation associated with G2019S-LRRK2 expression. [2] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 15.3 mg/mL (50.11 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2.5 mg/mL (8.19 mM), Sonication is recommended. |
| Keywords | PF-06447475 | PF06447475 | PF 06447475 | LRRK2 | Leucine-rich repeat kinase 2 | Inhibitor | inhibit | G2019S LRRK2 |
| Inhibitors Related | PFE-360 | IKK 16 | URMC-099 | GNE0877 | GSK2578215A | GNE-9605 | Indazole | CZC-54252 hydrochloride | GNE-7915 | LRRK2 inhibitor 1 | LRRK2-IN-7 | BIX 02565 |
| Related Compound Libraries | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Kinase Inhibitor Library | Anti-Parkinson's Disease Compound Library | Autophagy Compound Library | Post-Translational Modification Compound Library | Inhibitor Library | NO PAINS Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Covalent Inhibitor Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $139.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-07-14 | |
| $1980.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-05-21 | |
| $5.00 |
VIP8Y
|
Jinan Finer Chemical Co., Ltd
|
2026-07-20 | |
| $1.00 |
VIP8Y
|
Career Henan Chemical Co
|
2019-09-06 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY